Cellyan Biotechnology Co., Ltd income statement

In fiscal 2026, Cellyan Biotechnology Co., Ltd reported revenue of $13.4m, down 33.9% on the year before, operating income of −$2.4m (a -17.8% margin) and net income of −$1.1m, or −$0.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cellyan Biotechnology Co., Ltd: income statement, annual
Fiscal year	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Revenue	13	17	20	13
Cost of revenue	10	13	18	12
Gross profit	3	4	2	1
Operating income	−2	−2	−2	−2
Interest expense	0	0	0	0
Income before tax	1	2	0	−1
Income tax	0	0	0	0
Net income	1	1	−0	−1
Diluted EPS	$0.15	$0.18	−$0.00	−$0.07
Diluted shares (average)	7m	7m	10m	16m
EBITDA	−2	−2	−2	−2

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: COSM vs HKPD HKPD vs YI HKPD vs HSIC

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cellyan Biotechnology Co., Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cellyan Biotechnology Co., Ltd.